News

HORIZON-SESAR-2025 Calls: Boosting Aerial Innovation

Published on | 4 months ago

Programmes Digital, Industry & Space

The HORIZON-SESAR-2025 calls are part of the Horizon Europe programme, aimed at funding projects that strengthen the European Digital Sky.

Coordinated by the SESAR 3 Joint Undertaking, they drive the transformation of the Air Traffic Management (ATM) system through disruptive technologies, advanced automation, and environmental solutions.

These calls seek not only to improve the efficiency of Europe’s airspace but also to reduce aviation’s environmental footprint, optimise air navigation services, and ensure a safe transition towards future air mobility.

The HORIZON-SESAR-2025 calls target:

  • Aviation and technology companies.
  • Universities and research centres specialising in aviation, drones, and telecommunications.
  • Air Navigation Service Providers (ANSPs).
  • Innovative SMEs in advanced air mobility and sustainability.
  • European consortia involving partners from various Member States.

Transnational cooperation is prioritised to strengthen the European Research Area in air traffic management and innovative air mobility.

More information on the open calls

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1684 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.